BDSX Biodesix, Inc.

NASDAQ
$23.26

Biodesix, Inc. (BDSX) is confirmed to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.74 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.9% since its last earnings release on August 5, 2026.

Biodesix Beat Expectations, Reaffirms
Wednesday, August 5, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 4:00 PM ET
Earnings Whisper
($0.65)
vs ($0.74) +$0.09
Rev est $27.25M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $26.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Biodesix, Inc.

Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence.

Sector

Healthcare

Industry

Medical Labs & Research

Charts powered in part by Lightweight Charts™ by TradingView.